Opsoclonus myoclonus and ataxia syndrome with supraventricular tachycardia

Sydney Garner; Alec Giakas; Katherine Holder; Bernardo Galvan; Hollie Edwards

doi:10.1080/08998280.2022.2123666

Opsoclonus myoclonus and ataxia syndrome with supraventricular tachycardia

Proc (Bayl Univ Med Cent). 2022 Sep 20;36(1):109-110. doi: 10.1080/08998280.2022.2123666. eCollection 2023.

Authors

Sydney Garner¹, Alec Giakas¹, Katherine Holder², Bernardo Galvan², Hollie Edwards³

Affiliations

¹ University of South Carolina School of Medicine, Columbia, South Carolina.
² Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.
³ Prisma Health Children's Hospital, Columbia, South Carolina.

Abstract

Pediatric opsoclonus-myoclonus and ataxia syndrome (OMAS) is a neurologic disorder characterized by disturbances in eye movement, muscle jerks, ataxia, sleep, and mood. In approximately 50% of cases, it is a paraneoplastic syndrome associated with a neuroblastoma. In the remaining cases, it is believed that the tumor is occult, has involuted, or there is a preceding immune-stimulating event. While neuroblastomas can be associated with other paraneoplastic syndromes, supraventricular tachycardia (SVT) is rarely reported in the literature, and to our knowledge, this is the first case of SVT secondary to idiopathic OMAS. Confounding treatment toxicity, including intravenous immunoglobulin and other immunomodulatory drugs, should be screened for possible cardiovascular side effects in OMAS patients. The development of cardiac arrhythmias during OMAS treatment is not a contraindication to therapy. In these patients, arrhythmias should be controlled with vagal maneuvers or antiarrhythmics as needed while OMAS treatment is completed.

Keywords: Ataxia; myoclonus; opsoclonus; supraventricular tachycardia.

Publication types

Case Reports